Synthetic Lethal Interactions in Cancer Therapy

Curr Cancer Drug Targets. 2017;17(4):304-310. doi: 10.2174/1568009616666160426122736.

Abstract

Background: Silencing of two or more complementary signaling pathways can lead to cell death, while loss of any single genetic function does not show a severe phnotype, this kind of inter action is coined as "synthetic lethality". Nowadays, synthetic lethality has become a widely used anti-cancer strategy.

Method: We reviewed the synthetic lethal interactions exploited in anticancer therapies before 2016.

Conclusion: Synthetic lethality is a well proved anticancer strategy and more synthetic lethal interactions is being translated into clinical cancer therapies.

Keywords: PARP inhibitors; Synthetic lethality; cancer therapy; drug resistance; signaling pathways; targeted therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Cell Death / drug effects
  • Drug Discovery
  • Drug Screening Assays, Antitumor
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Signal Transduction

Substances

  • Antineoplastic Agents